Comeback for Avandia?

Once the world’s best-selling treatment for type 2 diabetes, GlaxoSmithKine’s Avandia is currently banned in Europe and severely restricted in the U.S – due to an increased risk of heart attack and stroke. But new recommendations from federal health advisors may change things. The New York Times reports, “A panel of experts voted Thursday to loosen restrictions [on Avandia], saying doctors should have more freedom to prescribe it to patients.”

The Food and Drug Administration advisory panel’s members voted after a two-day meeting to consider a new analysis of Avandia’s cardiovascular safety. Of the 26 members in attendance, 13 voted to relax safety restrictions, 7 voted to remove restrictions, 5 to keep them the same, and one panelist voted to withdraw Avandia from the market altogether.

Too little, too late

In 2007, Avandia was linked to possible heart trouble.
In 2007, Avandia was linked to possible heart trouble.

Even if the FDA does loosen restrictions, it may be too late for Glaxo. According to CNBC, panel members agreed that Avandia may never reach its former annual sales of $3.2 billion. “The train has left the station,” said Gerald van Belle, director of the Clinical Trials Center at the University of Washington. Glaxo’s patent on Avandia expired last year. Although another drug company has approval to sell a generic version, it has not done so.

Glaxo has settled a myriad of lawsuits filed by “tens of thousands” of patients who claim Glaxo failed to inform them about safety risks.  And, in an unprecedented case last summer, the drugmaker agreed to pay $3 billion to settle the largest case of healthcare fraud in U.S. history – resolving allegations that they had failed to provide safety data on Avandia to the FDA and had improperly marketed other drugs.

Moving forward

In a statement, Glaxo said it would work with the FDA as it considers any potential changes. Currently, Avandia may only be prescribed as a last resort to those who have not responded to other therapies – about 3000 patients, down from 120,000 before restrictions were put in place. The panel’s recommendation is not binding, but the FDA will take it into consideration when it makes its final decision, no word yet on when that will be.

Call 1-800-ELK-OHIO for a free consultation if you or a loved one has suffered from a dangerous drug or medical device

If you, a loved one or someone you know has been harmed by a recalled drug or defective medical device, you need the help of a proficient, experienced and determined law firm with the experience and resources to prove your case. Give Elk & Elk the opportunity to show you what a difference a law firm with our experience and resources can make in your life. We offer free, no-obligation telephone consultations at 1-800-ELK-OHIO 24 hours a day, seven days a week, 365 days a year. We also offer a no-cost, no-obligation online contact form. With the drug recall attorneys at Elk & Elk, there’s never a fee unless we have a successful outcome for you, and we’re here around the clock.

(Visited 1 times, 1 visits today)

One Reply to “Comeback for Avandia?”

  1. Avandia heart risks the drug maker for speaking out about the dangers which could be associated with the diabetes medication if FDA doesn’t slap a ban on Avandia, none of the physician would prefer to prescribe this drug.

Leave a Reply